MX2016009047A - Anticuerpos dirigidos contra interleucina-33 (il-33). - Google Patents

Anticuerpos dirigidos contra interleucina-33 (il-33).

Info

Publication number
MX2016009047A
MX2016009047A MX2016009047A MX2016009047A MX2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A
Authority
MX
Mexico
Prior art keywords
chain polypeptide
directed against
antibodies directed
against interleukin
binding agent
Prior art date
Application number
MX2016009047A
Other languages
English (en)
Inventor
A Horlick Robert
J King David
John Mcknight Andrew
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MX2016009047A publication Critical patent/MX2016009047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invención se refiere a un polipéptido de cadena pesada de inmunoglobulina aislado y un polipéptido de cadena ligera de inmunoglobulina aislado que se enlazan a interleucina-33 (IL-33). La invención proporciona un agente de enlace a IL-33 que comprende el polipéptido de cadena pesada de inmunoglobulina y el polipéptido de cadena ligera de inmunoglobulina anteriormente mencionados. La invención también proporciona vectores, composiciones, y métodos relacionados al uso del agente de enlace a IL-33 para tratar un trastorno en un mamífero que responde a inhibición de IL 33.
MX2016009047A 2014-01-10 2015-01-09 Anticuerpos dirigidos contra interleucina-33 (il-33). MX2016009047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925946P 2014-01-10 2014-01-10
PCT/US2015/010785 WO2015106080A2 (en) 2014-01-10 2015-01-09 Antibodies directed against interleukin-33 (il-33)

Publications (1)

Publication Number Publication Date
MX2016009047A true MX2016009047A (es) 2017-04-13

Family

ID=53524474

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009047A MX2016009047A (es) 2014-01-10 2015-01-09 Anticuerpos dirigidos contra interleucina-33 (il-33).
MX2020001272A MX2020001272A (es) 2014-01-10 2016-07-08 Anticuerpos dirigidos contra interleucina-33 (il-33).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001272A MX2020001272A (es) 2014-01-10 2016-07-08 Anticuerpos dirigidos contra interleucina-33 (il-33).

Country Status (14)

Country Link
US (3) US10059764B2 (es)
EP (1) EP3092253B1 (es)
JP (2) JP2017503506A (es)
KR (1) KR102446386B1 (es)
CN (1) CN106103480B (es)
AU (1) AU2015204674B2 (es)
BR (1) BR112016016020B1 (es)
CA (1) CA2936366A1 (es)
ES (1) ES2866935T3 (es)
MX (2) MX2016009047A (es)
NZ (1) NZ722445A (es)
RU (2) RU2693084C2 (es)
SG (2) SG11201605580RA (es)
WO (1) WO2015106080A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012991A (es) 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
KR102400060B1 (ko) 2013-12-26 2022-05-19 미쓰비시 타나베 파마 코퍼레이션 인간 항 il-33 중화 단일클론 항체
RU2693084C2 (ru) 2014-01-10 2019-07-01 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
SG11201805900YA (en) * 2016-01-14 2018-08-30 Anaptysbio Inc Inhibition of allergic reaction using an il-33 inhibitor
EP3448888A1 (en) * 2016-04-27 2019-03-06 Pfizer Inc Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201900464TA (en) * 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
HRP20240195T1 (hr) 2016-12-19 2024-04-26 Medimmune Limited Antitijela na lif i njihove primjene
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
KR102362006B1 (ko) 2017-02-10 2022-02-14 제넨테크, 인크. 항-트립타제 항체, 이의 조성물, 및 그의 용도
KR20230164197A (ko) 2017-04-13 2023-12-01 리제너론 파마슈티칼스 인코포레이티드 Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
TWI825025B (zh) 2017-08-31 2023-12-11 日商田邊三菱製藥股份有限公司 包含il-33拮抗劑的子宮內膜異位症治療劑
TW201922280A (zh) 2017-10-09 2019-06-16 美商安納普提斯生物公司 用於異位性皮膚炎之抗-il-33 療法
KR102417088B1 (ko) 2018-02-09 2022-07-07 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
TW202021983A (zh) 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF
JP2023501316A (ja) 2019-11-04 2023-01-18 メドイミューン・リミテッド 腎機能障害を治療するための抗ｉｌ－３３治療薬
AU2020379171A1 (en) 2019-11-04 2022-06-09 Medimmune Limited Methods of using IL-33 antagonists
JPWO2021157619A1 (es) 2020-02-05 2021-08-12
CR20220461A (es) 2020-03-13 2022-10-21 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
JP2023521061A (ja) 2020-04-06 2023-05-23 メドイミューン・リミテッド Ｉｌ－３３軸結合アンタゴニストによる急性呼吸窮迫症候群の治療
JP2023524866A (ja) 2020-05-11 2023-06-13 メドイミューン・リミテッド 抗ｉｌ－３３抗体の処方物
US20210380721A1 (en) * 2020-06-01 2021-12-09 University Of Kentucky Research Foundation Compounds and methods for use in connection with opioid use disorders
US20230255954A1 (en) * 2020-07-07 2023-08-17 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
KR20220022226A (ko) * 2020-08-18 2022-02-25 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
CN114249825A (zh) * 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038185A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
CA2614972C (en) 2005-07-18 2014-08-19 Amgen Inc. Human anti-b7rp1 neutralizing antibodies
WO2007130627A2 (en) 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
KR101676269B1 (ko) 2006-09-08 2016-11-15 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
WO2008103474A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
EP2310416A1 (en) * 2008-06-30 2011-04-20 Morphotek, Inc. Anti-gd2 antibodies and methods and uses related thereto
CN102369217A (zh) 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
NZ599315A (en) 2009-10-15 2014-05-30 Avaxia Biologics Inc Antibody therapeutics with local activity in the digestive tract
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
US8999343B2 (en) * 2010-08-16 2015-04-07 Amgen Inc. Antibodies that bind myostatin, compositions and methods
WO2012061360A2 (en) 2010-11-01 2012-05-10 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions
NZ609493A (en) 2010-12-16 2015-11-27 Genentech Inc Diagnosis and treatments relating to th2 inhibition
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
BR112014009962A2 (pt) * 2011-10-27 2019-09-24 Nkt Therapeutics Inc anticorpos humanizados para inkt
WO2013126834A1 (en) 2012-02-24 2013-08-29 Children's Hospital Medical Center Esophageal microrna expression profiles in eosinophilic esophagitis
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
CA2878516A1 (en) 2012-07-31 2014-02-06 Novartis Ag Treating inflammation using serelaxin
US20150250808A1 (en) 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
WO2014090800A1 (en) 2012-12-10 2014-06-19 Vib Vzw Novel interleukin-33 inhibitors
KR101780575B1 (ko) 2013-02-14 2017-09-21 건국대학교 산학협력단 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
CN111588848A (zh) 2013-08-12 2020-08-28 阿斯特拉捷利康股份公司 使用贝那利珠单抗降低哮喘恶化率的方法
KR101567758B1 (ko) 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물
JP6715767B2 (ja) 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
KR102400060B1 (ko) 2013-12-26 2022-05-19 미쓰비시 타나베 파마 코퍼레이션 인간 항 il-33 중화 단일클론 항체
RU2693084C2 (ru) 2014-01-10 2019-07-01 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP3134120B1 (en) 2014-04-21 2024-01-24 The Children's Hospital of Philadelphia Compositions and methods for treating cytokine-related disorders
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
MA50638A (fr) 2015-10-06 2020-08-05 Regeneron Pharma Biomarqueurs associés aux maladies médiées par l'interleukine-33 (il-33) et leurs utilisations
SG11201805900YA (en) 2016-01-14 2018-08-30 Anaptysbio Inc Inhibition of allergic reaction using an il-33 inhibitor

Also Published As

Publication number Publication date
SG10201805934RA (en) 2018-08-30
BR112016016020B1 (pt) 2024-02-27
WO2015106080A3 (en) 2015-09-11
AU2015204674B2 (en) 2020-09-03
JP6882702B2 (ja) 2021-06-02
US10059764B2 (en) 2018-08-28
EP3092253B1 (en) 2021-03-17
BR112016016020A2 (pt) 2018-05-22
RU2693084C2 (ru) 2019-07-01
WO2015106080A2 (en) 2015-07-16
EP3092253A4 (en) 2017-11-29
JP2017503506A (ja) 2017-02-02
KR102446386B1 (ko) 2022-09-22
US20180346562A1 (en) 2018-12-06
ES2866935T3 (es) 2021-10-20
RU2016132757A3 (es) 2018-07-16
RU2019118984A (ru) 2019-08-06
KR20160132006A (ko) 2016-11-16
CN106103480B (zh) 2021-10-22
US10836820B2 (en) 2020-11-17
EP3092253A2 (en) 2016-11-16
AU2015204674A1 (en) 2016-08-25
NZ722445A (en) 2022-07-01
CN106103480A (zh) 2016-11-09
RU2016132757A (ru) 2018-02-16
CA2936366A1 (en) 2015-07-16
SG11201605580RA (en) 2016-10-28
US20160333090A1 (en) 2016-11-17
US20210040198A1 (en) 2021-02-11
MX2020001272A (es) 2020-07-20
JP2020018309A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
MX2017012429A (es) Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3).
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2022005211A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2017009904A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
MX2015015037A (es) Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
NZ766356A (en) Anti-pd-1 antibodies
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
NZ724815A (en) Humanized antibodies that bind lgr5
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.
EA202092572A1 (ru) Композиции и способы обнаружения и лечения рака пищевода

Legal Events

Date Code Title Description
FG Grant or registration